Nanocapsules: A Novel Formulation of Ocular Drug Delivery System
DOI:
https://doi.org/10.37285/ijpsn.2024.17.6.10%20Abstract
Ocular drug delivery remains a significant challenge in the field of ophthalmology, where conventional eye drops often fall short in terms of drug bioavailability and duration of action. This review aims to evaluate the state of the art in ocular drug delivery, focusing on the emerging use of nanocapsules as a promising platform for a novel formulation of eye drops. Traditional eye drops are associated with limitations, such as rapid drug washout, poor corneal penetration, and patient non compliance due to frequent administration. Nanocapsules, with their nano-sized structures and core-shell designs, have garnered attention for their potential to address these challenges. The core-shell structure allows for the encapsulation of a wide range of ocular drugs, facilitating controlled release and prolonged drug retention on the ocular surface. Explored the effectiveness and safety of nanocapsules eye drops in various eye conditions, demonstrating their potential to revolutionize ocular drug delivery. Diseases such as glaucoma, macular degeneration, and dry eye syndrome may particularly benefit from this innovative approach. As the field of nanocapsules-based ocular drug delivery continues to evolve, the potential for improved therapeutic outcomes and enhanced patient quality of life becomes increasingly evident. This review calls for further research and development in this domain to unlock the full potential of nanocapsules as a novel formulation for ocular drug delivery systems.
Downloads
Keywords:
, Bioavailability, Bioavailability enhancement, sustained action, Targeted Drug Delivery, Safety, tolerability, Ocular drug delivery system, eye, ocular diseases., Nanocapsule, GlaucomaPublished
How to Cite
Issue
Section
References
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. Jama. 2014 May 14;311(18):1901-11.
Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. American journal of health-system pharmacy. 2005 Apr 1;62(7):691-9.
Vélez-Gómez MC, Vásquez-Trespalacios EM. Adherencia al tratamiento tópico del glaucoma, factores protectores yde riesgo; una revisión del tema. Archivos de la Sociedad Española de Oftalmología. 2018 Feb 1;93(2):87-92. 4. Cardigos J, Ferreira Q, Crisóstomo S, Moura-Coelho N, Cunha JP, Pinto LA, Ferreira JT. Nanotechnology-ocular devices for glaucoma treatment: a literature review. Current eye research. 2019 Feb 1;44(2):111-7.
Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Annals of Pharmacotherapy. 2002 Mar;36(3):504-11.
Weinreb RN, Khaw PT. Primary open-angle glaucoma. The lancet. 2004 May 22;363(9422):1711-20.
Phu J, Agar A, Wang H, Masselos K, Kalloniatis M. Management of open‐angle glaucoma by primary eye‐care practitioners: toward a personalised medicine approach. Clinical and Experimental Optometry. 2021 Apr 3;104(3):367-84.
Tang W, Zhang F, Liu K, Duan X. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta analysis. Medicine. 2019 Jul;98(30).
Schwartz GF, Patel A, Naik R, Lunacsek O, Ogbonnaya A, Campbell J. Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis. Ophthalmology Glaucoma. 2021 Mar 1;4(2):117-25.
Eraslan N, Ekici E, Celikay O. The effect of topical bimatoprost on corneal clarity in primary open-angle glaucoma: a longitudinal prospective assessment. International Ophthalmology. 2022 Mar 1:1-8.
Chan PP, Pang JC, Tham CC. Acute primary angle closure–treatment strategies, evidences and economical considerations. Eye. 2019 Jan;33(1):110-9.
Flores-Sánchez BC, Tatham AJ. Acute angle closure glaucoma. British Journal of Hospital Medicine. 2019 Dec 2;80(12):C174-9.
Li S, Tang G, Fan SJ, Zhai G, Lv J, Zhang H, Lu W, Jiang J, Lv A, Wang N, Cao K. Factors associated with blindness three months following treatment for acute primary angle glaucoma. British Journal of Ophthalmology. 2021 Apr 1;105(4):502-6.
You S, Liang Z, Yang K, Zhang Y, Oatts J, Han Y, Wu H. Novel discoveries of anterior segment parameters in fellow eyes of acute primary angle closure and chronic primary angle closure glaucoma. Investigative Ophthalmology & Visual Science. 2021 Nov 1;62(14):6-.
Nuessle S, Luebke J, Boehringer D, Reinhard T, Anton A. Akuter Winkelblock: Ein ophthalmologischer Notfall in der medizinischen Notaufnahme. Medizinische Klinik, Intensivmedizin Und Notfallmedizin. 2022;117(2):137.
Boland MV, Ervin AM, Friedman DS, Jampel HD, Hawkins BS, Vollenweider D, Chelladurai Y, Ward D, Suarez-Cuervo C, Robinson KA. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the US Preventive Services Task Force. Annals of internal medicine. 2013 Feb 19;158(4):271-9.
Day AC, Baio G, Gazzard G, Bunce C, Azuara-Blanco A, Munoz B, Friedman DS, Foster PJ. The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. British Journal of Ophthalmology. 2012 Sep 1;96(9):1162-7.
Schwartz, G. F., Hollander, D. A., & Williams, J. M. (2019). Evaluation of the Target Intraocular Pressure Model in Patients Requiring Additional Ocular Hypotensive Therapy to Control Intraocular Pressure in 1 Eye. Journal of Glaucoma, 28(2), 157-162.
Waisbourd, M., Parker, S., Ekici, F., Hassan, S., & Katz, L. J. (2014). Pharmacoeconomic considerations in glaucoma treatment. Current Opinion in Ophthalmology, 25(2), 110-115.
Castro-Balado A, Mondelo-García C, Zarra-Ferro I, Fernández-Ferreiro A. New ophthalmic drug delivery systems. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2020 Jul 1;44(4):149-57.
Oliveira AC, Oliveira PM, Cunha-Filho M, Gratieri T, Gelfuso GM. Latanoprost loaded in polymeric nanocapsules for effective topical treatment of alopecia. AAPS PharmSciTech. 2020 Nov;21:1-7.
Zhang A, Sun R, Ran M, Deng Y, Ge Y, Zhu Y, Tao X, Shang L, Gou J, He H, Yin T. A novel eyes topical drug delivery system: CsA-LNC for the treatment of DED. Pharmaceutical Research. 2020 Jul;37:1-4.
Sun R, Zhang A, Ge Y, Gou J, Yin T, He H, Wang Y, Zhang G, Kong J, Shang L, Tao X. Ultra-small-size Astragaloside-IV loaded lipid nanocapsules eye drops for the effective management of dry age-related macular degeneration. Expert Opinion on Drug Delivery. 2020 Sep 1;17(9):1305-20.
Rebibo L, Tam C, Sun Y, Shoshani E, Badihi A, Nassar T, Benita S. Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. Journal of Controlled Release. 2021 May 10;333:283-97.
Calvo P, Alonso MJ, VILA‐JATO JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. Journal of pharmacy and pharmacology. 1996 Nov;48(11):1147-52.
Zhang A, Sun R, Ran M, Deng Y, Ge Y, Zhu Y, Tao X, Shang L, Gou J, He H, Yin T. A novel eyes topical drug delivery system: CsA-LNC for the treatment of DED. Pharmaceutical Research. 2020 Jul;37:1-4.
Fessi HP, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. International journal of pharmaceutics. 1989 Oct 1;55(1):R1-4.
Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. science. 1997 Aug 29;277(5330):1232-7.
Bodmeier R, Chen H, Paeratakul O. A novel approach to the oral delivery of micro-or nanoparticles. Pharmaceutical research. 1989 May;6:413-7.
Dusek, K., et al. "Biodegradable nanocapsules prepared by layer-by-layer technique." Journal of Colloid and Interface Science, 2006 may 293(2).
Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. Journal of pharmaceutical sciences. 1996 May 1;85(5):530-6.
Lou J, Hu W, Tian R, Zhang H, Jia Y, Zhang J, Zhang L. Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles. International journal of nanomedicine. 2014 May 21:2517-25.
Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Advanced drug delivery reviews. 2005 Dec 13;57(14):2010-32.
Dubey V, Mohan P, Dangi JS, Kesavan K. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. International journal of biological macromolecules. 2020 Jun 1;152:1224-32.
Swaminathan S, Vavia PR, Trotta F, Cavalli R. Nanosponges encapsulating dexamethasone for ocular delivery: formulation design, physicochemical characterization, safety and corneal permeability assessment. Journal of biomedical nanotechnology. 2013 Jun 1;9(6):998-1007.
Losa C, Alonso Mj, Vila Jl, Orallo F, Martinez J, Saavedra Ja, Pastor Jc. Reduction of cardiovascular side effects associated with ocular administration of metipranolol by inclusion in polymeric nanocapsules. Journal of Ocular Pharmacology and Therapeutics. 1992;8(3):191-8.
Rebibo L, Tam C, Sun Y, Shoshani E, Badihi A, Nassar T, Benita S. Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. Journal of Controlled Release. 2021 May 10;333:283-97.
Le Bourlais CA, Chevanne F, Turlin B, Acar L, Zia H, Sado PA, Needham TE, Leverge R. Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study. Journal of microencapsulation. 1997 Jan 1;14(4):457-67.
Katzer T, Chaves P, Bernardi A, Pohlmann A, Guterres SS, Ruver Beck RC. Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. Journal of microencapsulation. 2014 Sep 1;31(6):519-28.
Mohan P, Rangari VD, Kesavan K. Cationic Chitosan/Pectin Polyelectrolyte Nanocapsules of Moxifloxacin as Novel Topical Management System for Bacterial Keratitis. Current Eye Research. 2022 Nov 2;47(11):1498-507.
Ushirobira CY, Afiune LA, Pereira MN, Cunha-Filho M, Gelfuso GM, Gratieri T. Dutasteride nanocapsules for hair follicle targeting: Effect of chitosan-coating and physical stimulus. International journal of Biological macromolecules. 2020 May 15;151:56-61.
Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Poly (ε-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharmaceutical research. 1993 Mar;10:386-90.
Pohlmann AR, Fonseca FN, Paese K, Detoni CB, Coradini K, Beck RC, Guterres SS. Poly (ϵ-caprolactone) microcapsules and nanocapsules in drug delivery. Expert opinion on drug delivery. 2013 May 1;10(5):623-38.
Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Nanocapsules de β-bloquants: un nouveau vecteur de médicaments en ophthalmologie: application au traitement médical du glaucome chez le lapin. Journal français d'ophtalmologie. 1991;14(6-7):371-5.
Perez VL, Wirostko B, Korenfeld M, From S, Raizman M. Ophthalmic drug delivery using iontophoresis: recent clinical applications. Journal of Ocular Pharmacology and Therapeutics. 2020 Mar 1;36(2):75-87.
Luo L, Yang J, Oh Y, Hartsock MJ, Xia S, Kim YC, Ding Z, Meng T, Eberhart CG, Ensign LM, Thorne JE. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. Journal of Controlled Release. 2019 Feb 28;296:68-80.
